CWR22: The first human prostate cancer xenograft with strongly: Androgen-dependent and relapsed strains both in vivo and in soft agar

Moolky Nagabhushan, Casey M. Miller, Theresa P. Pretlow, Joseph M. Giaconia, Nancy L. Edgehouse, Stuart Schwartz, Hsing Jien Kung, Ralph W. De Vere White, Paul H. Gumerlock, Martin I. Resnick, Saeid B. Amini, Thomas G. Pretlow

研究成果: 雜誌貢獻文章同行評審

217 引文 斯高帕斯(Scopus)

摘要

Most patients' prostate cancers respond to androgen deprivation but relapse after periods of several months to years. Only two prostate cancer xenografts, LNCaP and PC-346, have been reported to be responsive to androgen deprivation and to relapse subsequently. Both of these tumors shrink slightly, if at all, and relapse less than 5 weeks after androgen withdrawal. After androgen withdrawal, the human primary prostate cancer xenograft CWR22 regresses markedly, and prostate-specific antigen (PSA) falls up to 3000-fold in the blood of mice. PSA usually returns to normal. In some animals, the tumor relapses and is then designated CWR22R. In these animals, PSA starts to rise approximately 2-7 months, and tumor begins to grow 3-10 months after castration. Animals with CWR22 need to be euthanized because of large tumors 6-12 weeks after the transplantation of CWR22. Androgen withdrawal prolongs life approximately 3-4-fold.
原文英語
頁(從 - 到)3042-3046
頁數5
期刊Cancer Research
56
發行號13
出版狀態已發佈 - 七月 1 1996
對外發佈Yes

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

指紋 深入研究「CWR22: The first human prostate cancer xenograft with strongly: Androgen-dependent and relapsed strains both in vivo and in soft agar」主題。共同形成了獨特的指紋。

引用此